[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fulgent Genetics Inc (FLGT)

Fulgent Genetics Inc (FLGT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 474,762
  • Shares Outstanding, K 29,747
  • Annual Sales, $ 322,670 K
  • Annual Income, $ -60,510 K
  • EBIT $ -98 M
  • EBITDA $ -79 M
  • 60-Month Beta 0.88
  • Price/Sales 1.39
  • Price/Cash Flow N/A
  • Price/Book 0.43

Options Overview Details

View History
  • Implied Volatility 51.41% (-2.24%)
  • Historical Volatility 52.07%
  • IV Percentile 47%
  • IV Rank 15.75%
  • IV High 162.19% on 03/18/26
  • IV Low 30.69% on 09/02/25
  • Expected Move (DTE 3) 1.60 (10.10%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 224
  • Volume Avg (30-Day) 140
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 3,701
  • Open Int (30-Day) 3,787
  • Expected Range 14.22 to 17.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.79
  • Number of Estimates 1
  • High Estimate $-0.79
  • Low Estimate $-0.79
  • Prior Year $-0.25
  • Growth Rate Est. (year over year) -216.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.04 +12.68%
on 05/01/26
16.52 -4.24%
on 04/17/26
+1.39 (+9.63%)
since 04/10/26
3-Month
13.46 +17.53%
on 03/03/26
24.91 -36.48%
on 02/26/26
-7.18 (-31.22%)
since 02/11/26
52-Week
13.46 +17.53%
on 03/03/26
31.04 -49.03%
on 11/25/25
-3.88 (-19.70%)
since 05/09/25

Most Recent Stories

More News
Fulgent Reports First Quarter 2026 Financial Results

Reiterates revenue guidance for fiscal year 2026 Executed on stock repurchase program; purchased approximately 2.6 million shares in the first quarter of 2026 using $40.1 million in cash...

FLGT : 15.82 (-0.88%)
Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today...

FLGT : 15.82 (-0.88%)
Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today...

FLGT : 15.82 (-0.88%)
FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent Genetics Inc.

The law firm of Kirby McInerney LLP continues its investigation on behalf of Fulgent Genetics Inc. (“Fulgent” or the “Company”) (NASDAQ:FLGT) investors concerning the Company’s...

FLGT : 15.82 (-0.88%)
FULGENT GENETICS INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

The law firm of Kirby McInerney LLP is investigating potential claims against Fulgent Genetics Inc. (“Fulgent” or the “Company”) (NASDAQ:FLGT). The investigation concerns whether...

FLGT : 15.82 (-0.88%)
Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced the completion...

FLGT : 15.82 (-0.88%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT

NEW YORK , March 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ: FLGT).  Such investors are...

FLGT : 15.82 (-0.88%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT

NEW YORK , March 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ: FLGT). Such investors are advised...

FLGT : 15.82 (-0.88%)
Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results

Revenue of $83.3 million, growing 9% year-over-year GAAP gross profit of $32.6 million, or GAAP gross margin of 39.1%; Non-GAAP gross profit of $34.2 million, or Non-GAAP gross margin...

FLGT : 15.82 (-0.88%)
Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today...

FLGT : 15.82 (-0.88%)

Business Summary

Fulgent Genetics, Inc. provides genetic testing services to physicians with clinically actionable diagnostic information. The company's technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process...

See More

Key Turning Points

3rd Resistance Point 16.65
2nd Resistance Point 16.41
1st Resistance Point 16.12
Last Price 15.82
1st Support Level 15.59
2nd Support Level 15.35
3rd Support Level 15.06

See More

52-Week High 31.04
Fibonacci 61.8% 24.32
Fibonacci 50% 22.25
Fibonacci 38.2% 20.18
Last Price 15.82
52-Week Low 13.46

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.